In an article for STAT, Ami Gopalan touches on CVS Health’s latest effort to nudge drug makers to reduce launch prices to a reasonable level. With an increase of payers use of value assessments such as ICER, manufacturers need to come to terms with a health care marketplace that increasingly ties access to competitive cost-effectiveness.

To read the full article, please click here.